REVLIMID U.S. Prescribing Information
REVLIMID U.S. Prescribing Information - Bristol Myers Squibb
REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma. (MCL) whose disease has relapsed or progressed after two prior therapies, ...
REVLIMID (lenalidomide) - accessdata.fda.gov
See full prescribing information for. REVLIMID. REVLIMID (lenalidomide) capsules, for oral use. Initial U.S. Approval: 2005. WARNING: EMBRYO-FETAL TOXICITY, ...
REVLIMID [lenalidomide] capsules, for oral use - accessdata.fda.gov
See full prescribing information for. REVLIMID. REVLIMID [lenalidomide] capsules, for oral use. Initial US Approval: 2005. WARNING: EMBRYO-FETAL TOXICITY, ...
REVLIMID® (lenalidomide) - Official Patient Website
REVLIMID is a prescription medicine, used to treat adults with multiple myeloma (MM) in combination with the medicine dexamethasone, or as maintenance ...
Multiple Myeloma Treatment Option | REVLIMID® (lenalidomide)
REVLIMID (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM).
Revlimid (Lenalidomide) | International Myeloma Foundation
In the current prescribing information for Revlimid, the Boxed Warnings are the risks of thrombocytopenia, neutropenia, and embryo-fetal toxicity. For patients ...
REVLIMID® (lenalidomide) | Indications and Important Safety ...
DRd is indicated for the treatment of adult patients with relapsed or refractory MM who have received at least one prior therapy. Information about DRd does not ...
Label: LENALIDOMIDE capsule - DailyMed
For concomitant therapy doses, see Full Prescribing Information (2.1, 14.1). DOSAGE FORMS AND STRENGTHS. Capsules: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg ...
Products covered under Lenalidomide REMS
Generic Products ; Lenalidomide, lenalidomide, Exelan Pharmaceuticals, Inc. 1-302-631-5048. U.S. Prescribing Information · Medication Guide ; Lenalidomide ...
Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy ...
Revlimid (lenalidomide) capsules [prescribing information]. Summit, NJ: Celgene Corporation; February 2015. 13. US Food and Drug Administration. FDA ...
REVLIMID Product Monograph - Bristol Myers Squibb
bSeverity Grades are based on US ... Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about ...
Prescribing Information for NINLARO® (ixazomib)
lenalidomide prescribing information if dose reduction is needed for lenalidomide. ... Information has been approved by the U.S. Food and Drug Administration ...
Revlimid, INN-lenalidomide - European Medicines Agency
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked ...
EMPLICITI® (elotuzumab) | Official Patient Website
Further information about the POMALYST REMS program is available at www.pomalystrems.com or by telephone at 1-888-423-5436. Before prescribing REVLIMID or ...
Refer to lenalidomide, pomalidomide, or thalidomide prescribing information ... This Patient Information has been approved by the U.S. Food and Drug ...
REVLIMID(lenalidomide) capsules - HemOnc.org
See full prescribing information for REVLIMID. REVLIMID(lenalidomide) ... This Medication Guide has been approved by the US Food and. Drug Administration.
Explore Treatment - POMALYST® (pomalidomide)
This site is intended for US audiences only. Join a Support Program ... Please see full Prescribing Information, including Boxed WARNINGS, for REVLIMID.
Reimbursement and Coding for REVLIMID®
Please see Important Safety Information on pages 17–21 and U.S. Full Prescribing Information, including Boxed WARNINGS, for REVLIMID. A REFERENCE GUIDE TO.
SARCLISA® (isatuximab-irfc) | Official Patient Website
Info for patients about the efficacy and safety of SARCLISA (a therapy for multiple myeloma) and how SARCLISA works. See Important Safety & Prescribing ...
SARCLISA® (isatuximab-irfc) | Official HCP Website
Refer to the pomalidomide or lenalidomide prescribing information on use during pregnancy. ... This information is intended for US Healthcare Professionals only.